Screener
Crinetics Pharmaceuticals CRNX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's other income, net (note 6)?
- Crinetics Pharmaceuticals (CRNX) reported other income, net (note 6) of -$131K in Q1 2026.
- How has Crinetics Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Crinetics Pharmaceuticals's other income, net (note 6) increased by 35.5% year-over-year, from -$203K to -$131K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Crinetics Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude